

apy and cisplatin (believed to be a radiosensitizing agent) is controversial. Improved local control and survival from adding this compound to radiation has been demonstrated in one study, but at least two others studies were negative. The interpretation of many studies is difficult due to small patient samples and methodological flaws. It may be concluded therefore that chemotherapy may have a role as an adjunct to radiation in locally advanced NSCLC, but the gain from this approach should be weighted against increased early and late toxicity. Moreover, improvement of similar magnitude has been achieved with the use of modified radiotherapy techniques (hyperfractionation, CHART). A possible benefit from combined modality treatment should therefore be confirmed in further research.

1292

Non-small cell lung cancer: How extensive should surgery be?

J. Schirren, P. Schneider, Th. Muley, H. Bülzebruck, H. Dienemann, I. Vogt-Moykopf. *Department of Thoracic Surgery, Thoraxklinik Heidelberg, FRG*

Objective: Surgery is the treatment of choice in stage I and II bronchial carcinoma (BC). In stage III with extrapulmonary structures/organs involved, however, operative treatment is discussed controversially. Involvement of peripheral and mediastinal structures requires extensive interventions, e.g. mediastinal lymph node dissection and/or broncho- and angioplastic procedures.

Material and Methods: 6907 patients with BC, admitted to our institution between 1984 and 1994, were analysed. 2464 patients (36%) were resected.

Results: R₀-resection was achieved in 1996 patients, including 454 cases of BC stage IIIA, and 323 cases of BC stage IIIB. R₀-resection rates were 81% and 58%, respectively. 5-yr-survival was 26% in stage IIIA and 19% in IIIB. 5-yr-survival rates vary in correlation to spread of lymph node metastases, in case of stage IIIA between 39% and 14%. Stage IIIB collectives showed 5-yr-survival rates between 24% and 14%, respectively. Mediastinal lymph node involvement, therefore, appears to be a relevant prognostic factor. 30-day-mortality for all R₀-resected stage III tumours was 9%.

Conclusions: Surgery in BC stage III offers potential cure after complete resection. Adequate surgical management necessarily encompasses technically complicated procedures. A close interdisciplinary cooperation is required.

1293

New drugs and their possible impact on patient outcome

H. Bleiberg. *GI Unit, CHU Bordet, Brussels, Belgium*

CPT-11 is a semi-synthetic water soluble derivative of camptothecin. It is administered at the dose of 350 mg/sqm every 3 weeks (wks). Overall 455 patients (pts) have been treated in phase II studies. The response rate (RR) was 12.9%, stable disease (SD) 42%. Overall median survival (ms) was 9 months (mts), 14.5 for partial (P) R and 12.5 for SD. 61% of pts with PR or SD had pain relief attributable to CPT-11. Toxicity include short lasting neutropenia, early and delayed diarrhea (dd), nausea (n), vomiting (v), hair loss, fatigue. dd was significantly reduced with prompt administration of loperamide and antibiotics starting after 24 hrs if dd was not resolved.

Tomudex is a specific TS inhibitor administered at the dose of 3 mg/sqm every 3 wks. Compared to 5FU/folinic acid (FA) regimen in 3 large randomised studies, RR and toxicities were comparable. Improved PS and weight gain was demonstrated in both arms. Overall ms was comparable in 2 trials and superior for 5FU/FA in one.

Oxaliplatin is a non-nephrotoxic third generation platinum complex. It is given at the dose of 130 mg/sqm over 2 hrs in 5% glucose every 3 wks. Dose-limiting toxicity is a peripheral dysesthesia aggravated by cold. It has been investigated, mainly, in combination with continuous infusion of 5FU. RR of 50% to 28% have been reported for 1st and 2nd line treatment respectively. ms was 16 and 12 mts. 20 to 30% of pts with liver and lung metastases could be reoperated with a curative aim. New agents with various mechanism of action provide reason for optimism regarding the management of pts with advanced disease.

1294

Intense local therapy in resectable rectal cancer

Felipe A. Calvo. *For the Spanish Group of IORT; Hospital General Universitario Gregorio Marañón Madrid; Clínica Universitaria de Navarra (Pamplona). Instituto Madrileño de Oncología, Madrid, Spain*

Purpose: To describe methodology and results in rectal cancer combining preoperative chemoradiation, radical surgical resection and intraoperative electron irradiation (IORT).

Methods & Materials: From 8/95 to 6/96 76 patients with localized rectal cancer were treated with preoperative irradiation (40–50 Gy), simultaneous 5FU iv ci (500–1000 mg/m²) +/- CBDCA 55 mg iv, d 1–4/21–24 of radiotherapy. Radical surgery was performed 4–6 weeks after the completion of the neoadjuvant segment. IORT electron boost was added to the presacral space (10–15 Gy) after tumor resection. Adjuvant chemotherapy using 5FU-LV was recommended to patients with B2-C tumor downstage. Pretreatment clinical findings showed: mobile disease (9%), tethered (49%) and fixation (42%).

Results: Tolerance to the treatment program was acceptable. Pathologic tumor downstaging identified 25% of pT₀/pT_{mic} surgical specimens. With a median follow-up of 24 months (range +3 to +99 months) patterns of tumor progression has shown 1 mixed recurrence (anastomotic site + lung) and 9 systemic failures. Actuarial cause specific survival is projected 72% at 8 years.

Conclusion: Intense local therapy is feasible in resectable rectal cancer patients in the context of an expert group in IORT and chemoradiation. Pelvic failure has been eradicated (presacral IORT boosted region). Tolerance to the integral treatment intensity was acceptable. Up dated results to May 97 will be presented.

1295

Frontiers in the management of colorectal cancer – Combined modality treatment

B. Glimelius. *Department of Oncology, University of Uppsala, Uppsala, Sweden*

Even after apparently curative surgery for colorectal cancer, microscopic deposits are frequently left. These deposits, each containing between 10⁶–10⁸ cells may be eradicated by radiotherapy, chemotherapy or immunotherapy resulting in improved disease-free and overall survival. Radiotherapy is the most effective modality, potentially killing 10⁶–10⁸ cells if the doses are sufficiently high but is limited to a region such as the pelvic cavity in rectal cancer. Preoperative radiotherapy, being more dose-efficient than postoperative, has also reduced local failure rates and improved survival. Chemotherapy has limited cell kill effects, but has yet improved survival to a limited but clinically relevant extent in colon Dukes' C. The relative benefits may be as large also in Dukes' stage, but the absolute gains are then much less due to fewer recurrences and the routine use of the additional treatment is then questionable. Both radiotherapy and chemotherapy may have acute and late adverse effects. Inappropriate techniques, such as used in certain radiotherapy trials, have also caused both acute and late effects, at least partly counterbalancing the positive effects. Each modality must be used in an optimized way. This also relates to the surgery. If the surgical techniques are optimized, such as they could be in rectal cancer, the relative gains by for example preoperative radiotherapy may not change, or they may even increase, but the absolute gains, and thus cost-effectiveness, may decrease. A review of recent results from controlled clinical trials will be made and directions for future improvements in outcome presented.

1296

To 5-FU or not to 5-FU? When, how and why to use the new active agents in advanced colorectal cancer

E. Cvitkovic. *FSMSIT, Hop Paul Brousse, Villejuif, France*

Patient characteristics, disease history and pretreatment characteristics should be determinant in the choice of systemic treatment in ACRC. The availability of modern imaging and reliable markers should be fully exploited now that a surge in surgical enthusiasm and molecular pharmacology tumor markers: p53, thymidilate synthase, mismatch repair defects, ADCC presence are put forward as putative natural history and treatment dependent prognostic factors. New thymidilate synthase active drugs, CPT-11 and Oxaliplatin have proven viable alternatives to 5-FU. The current prevalence of previous adjuvant treatment in metastatic disease populations and the simultaneous availability of new active agents are opportunities not to